Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|June 2, 2004
- Pharmaceutical Technology-06-02-2004
- Volume 28
- Issue 6
Will CROs Take On the Risks of Strategic Outsourcing?
Author(s)Jim Miller
It's not clear whether contract service providers can deliver the performance improvements and costs savings that drug companies expect from large, long-term, semi-exclusive contracts.
Advertisement
Articles in this issue
over 22 years ago
Microbial Testing in Support of Aseptic Processingover 22 years ago
June 2004over 22 years ago
Uniformity of Bioprocessing Equipment Manufacturingover 22 years ago
Research Tips To Find Packaging Facts Fastover 22 years ago
New Technologies Optimize Biotech Process Efficiencyover 22 years ago
Battles Escalate Over Prescription Drug Importsover 22 years ago
USP's Semi-Hemiquinquennial Meetingover 22 years ago
In the Spotlight - June 2004Advertisement
Related to this article
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Shilpa Pharma Lifesciences Limited will launch a new small-molecule CDMO at CPHI Milan in October.
This article explains the 4 shifts enabling faster, lower-risk, commercially successful biologics technology transfer.
Advertisement
Advertisement